Allergan's turnover from eyecare pharmaceuticals increased by 12.7 percent to $403.4 million in the 3rd quarter ended Sept. 29, and in constant currencies they were up by 11.5 percent. The company's total revenues climbed to $806.8 million, as compared to $611.5 million in the year-ago period. For the first nine ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
To continue reading this article register now.